Invention Title:

A CANNABINOID MIXTURE

Publication number:

US20240122947

Publication date:

2024-04-18

Section:

Human necessities

Class:

A61K31/658

Inventors:

Robert WALTON Liverpool, Merseyside, Great Britain (UK)

Mark TUCKER Liverpool, Merseyside, Great Britain (UK)

Debbie NASH Aberystwyth, Ceredigion, Great Britain (UK)

Nathan ALLEN Aberystwyth, Ceredigion, Great Britain (UK)

Ruth WONFOR Aberystwyth, Ceredigion, Great Britain (UK)

Ifat SHAH Aberystwyth, Ceredigion, Great Britain (UK)

Assignees:

Aberystwyth University Aberystwyth, Ceredigion, Great Britain (UK)

TTS Pharma Ltd Liverpool, Merseyside, Great Britain (UK)

Applicants:

ABERYSTWYTH UNIVERSITY Aberystwyth Ceredigion, Great Britain (UK)

TTS Pharma Ltd Liverpool, Merseyside, Great Britain (UK)

Drawings (4 of 13)

Smart overview of the Invention

A composition is proposed that combines cannabidiol (CBD) with various cannabinoids including cannabidiolic acid (CBDA), cannabigerol (CBG), and cannabigerolic acid (CBGA). This mixture is aimed at treating or preventing inflammation and related disorders, particularly those associated with interleukin-6 (IL-6) production. The formulation may also extend to food and beverage products that incorporate these cannabinoids for therapeutic purposes.

Current Market Landscape

The market for cannabinoid compositions has been expanding, with various products available, such as broad-spectrum CBD oils. However, existing formulations often lack the inclusion of CBDA. Previous studies have explored the properties of cannabinoid extracts but have not disclosed specific therapeutic uses. Notably, some cannabinoid products like Nabiximols (Sativex) have shown benefits in managing pain related to rheumatoid arthritis, indicating a demand for more effective formulations.

Therapeutic Efficacy

The proposed composition demonstrates surprising effectiveness in addressing inflammation and related disorders. The inclusion of CBDA alongside CBD enhances the anti-inflammatory properties, making it suitable for conditions linked to heightened Pattern Recognition Receptor (PRR) activation or increased IL-6 levels. This could potentially benefit patients suffering from a wide range of inflammatory diseases, including rheumatoid arthritis, asthma, and even certain cancers.

Composition Details

The formulation may also contain terpenes, with specified ratios to cannabinoids to optimize therapeutic effects. The concentration of cannabinoids can range from 0.03% to 30% by weight, while terpenes may be included at levels from 0.01% to 10%. Preferred terpenes include terpinolene and others such as alpha-humulene and beta-caryophyllene, which may enhance the overall efficacy of the composition.

Potential Applications

This cannabinoid mixture not only aims to treat clinical conditions but also addresses non-clinical inflammation. The versatility of the composition allows for its incorporation into various products, offering a novel approach to managing inflammation effectively. The detailed ratios and combinations of cannabinoids and terpenes provide a foundation for further research and development in cannabinoid-based therapies.